Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 16 of 16
Jan 6, 2026The biotech company’s innovative RNAi-based therapies showed encouraging outcomes in early clinical trials targeting obesity, highlighting gene-silencing technology’s expanding role in metabolic diseases.
Jan 6, 2026Arrowhead Pharmaceuticals reported that its gene-silencing candidates were successful in helping people with obesity lose fat, marking an advancement in RNA medicine aimed at managing obesity.
Jan 6, 2026Arrowhead's gene-silencing drugs demonstrated efficacy in reducing fat accumulation in early obesity studies. This approach could complement existing therapies by tackling the biology of obesity through RNA interference technology.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.